Cariprazine hydrochloride orally disintegrating tablets with similar dissolution behaviors in different specifications and preparation method thereof

By using a mixture of microcrystalline cellulose and mannitol or lactose as fillers, combined with crosslinked povidone and other ingredients, the carylazine hydrochloride oral collapse tablets were prepared through the powder mixing direct pressure process, and the preparation process in the prior art was solved The problem of complex and inconsistent dissolution behavior achieves rapid dissolution and bioequivalence of products of different specifications, reducing production costs.

CN118526462BActive Publication Date: 2024-11-15HQ PHARMA (SHANDONG) CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411004250.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-15
Estimated Expiration
2044-07-25

AI Technical Summary

Technical Problem

The existing cariprazine hydrochloride oral collapse tablet preparation process is complex, the production cost is high, and the dissolution behavior of different specifications is different, which affects the performance and control of drug efficacy.

Method used

The mixture of microcrystalline cellulose and mannitol or lactose is used as fillers, combined with cross-linked povidone, colloidal silica and other components, and different specifications of carriparazine hydrochloride oral collapse tablets are prepared through the powder mixing direct pressure process. Reduce preparation difficulty and quality risks, and ensure that the dissolution behavior of products of different specifications is similar.

Benefits of technology

The rapid dissolution behavior of different specifications of carylaprazine hydrochloride oral collapse tablets in different pH media is achieved, which improves the bioequivalence and production stability of the drug and reduces production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention provides a cariprazine hydrochloride orodisintegrating tablet and preparation method with similar dissolution behaviors of different specifications, and relates to the field of medical technology. The cariprazine hydrochloride orodisintegrating tablet of the present invention, according to weight parts, includes components: 0.5-6.52 parts of cariprazine hydrochloride, 85-95 parts of fillers, 0.5-5 parts of disintegrants, 0.5-5 parts of glidants, 0.1-2 parts of sweeteners and 0.1-2 parts of lubricants; the filler is a mixture of microcrystalline cellulose and mannitol, or a mixture of microcrystalline cellulose and lactose. The present invention adopts a mixed powder direct compression process to prepare cariprazine hydrochloride orodisintegrating tablets, which not only reduces the difficulty, quality risk and production cost of the preparation method, but also the prepared cariprazine hydrochloride orodisintegrating tablets have different specifications, and the dissolution behaviors of products of different specifications are similar, which improves quality control.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and particularly relates to cariprazine hydrochloride orally disintegrating tablets with different specifications and similar dissolution behaviors and a preparation method thereof. Background Art

[0002] Cariprazine hydrochloride is a partial agonist of D2 / D3 receptors. Cariprazine hydrochloride preferentially binds to D3 receptors. Compared with traditional psychotropic drugs that act on D2 receptors alone, cariprazine hydrochloride has the advantage of less incidence of extrapyramidal side effects.

[0003] Cariprazine hydrochloride capsules can be used to treat mania and mixed symptoms of schizophrenia and dominant bipolar disorder, but cariprazine hydrochloride capsules are not easy to swallow. Orodisintegrating tablets are tablets that can disintegrate in the mouth without drinking water. When taking, place the tablet on the tongue without taking it with water. The tablet will disintegrate and be swallowed into the stomach with saliva.

[0004] Chinese invention patent CN107970217A discloses a cariprazine orally disintegrating tablet and a preparation method thereof, wherein the orally disintegrating tablet comprises the following components in percentage by mass: cariprazine hydrochloride 0.8%-3.6%, binder 0-2.0%, disintegrant 16%-48%, diluent and lubricant. The cariprazine orally disintegrating tablet prepared by the invention can disintegrate rapidly in the oral cavity and dissolve rapidly; and the disintegrating tablet has good hardness and wear resistance, can improve the patient's compliance, reduce the burden on the guardian, effectively prevent the mentally ill patient from hiding and vomiting the medicine, and improve the treatment effect.

[0005] Chinese invention patent CN102014909A discloses a solid preparation for oral administration, which comprises cariprazine hydrochloride, excipients, binders and disintegrants; lactose is used as the main excipient, and the excipients also include crystalline cellulose and / or starch; the binder is selected from at least one of hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, methyl cellulose, povidone, and polyvinyl alcohol; the disintegrant is selected from at least one of sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, powdered agar, and cross-linked polyvinyl pyrrolidone. The invention shows that when mannitol or anhydrous calcium hydrogen phosphate is used as part of the excipient in the preparation, or when only crystalline cellulose is used as an excipient, a large amount of related substances will be produced. However, when lactose is used as the main excipient, cariprazine hydrochloride cannot be stably stored without the addition of cyclodextrin.

[0006] In the above invention, during the preparation process of cariprazine hydrochloride orally disintegrating tablets, a binder needs to be added for granulation, the production process is complicated, the process difficulty is high, and wetting and drying increase the risk of impurity growth and over-limit during the stability of the drug. Moreover, the dissolution behavior of cariprazine hydrochloride orally disintegrating tablets of different specifications is different, which affects the exertion and control of drug efficacy.

[0007] Based on this, the present invention uses specific types and amounts of auxiliary materials and adopts a mixed powder direct compression process to prepare cariprazine hydrochloride orally disintegrating tablets, which not only reduces the difficulty, quality risk and production cost of the preparation method, but also the prepared cariprazine hydrochloride orally disintegrating tablets have different specifications, and the dissolution behaviors of cariprazine hydrochloride orally disintegrating tablets of different specifications are similar. Summary of the invention

[0008] In view of the problems existing in the prior art, the present invention provides a cariprazine hydrochloride orally disintegrating tablet with different specifications and similar dissolution behavior and a preparation method thereof. The prepared cariprazine hydrochloride orally disintegrating tablet has different specifications (1.5 mg-6.0 mg cariprazine), and the dissolution behaviors of products with different specifications are similar.

[0009] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0010] On the one hand, the present invention provides a cariprazine hydrochloride orally disintegrating tablet with different specifications and similar dissolution behavior, which comprises the following components in parts by weight: 0.5-6.52 parts of cariprazine hydrochloride, 85-95 parts of filler, 0.5-5 parts of disintegrant, 0.5-5 parts of glidant, 0.1-2 parts of sweetener and 0.1-2 parts of lubricant;

[0011] The filler is a mixture of microcrystalline cellulose and mannitol, or a mixture of microcrystalline cellulose and lactose;

[0012] When the filler is a mixture of microcrystalline cellulose and mannitol, the weight ratio of microcrystalline cellulose to mannitol is 60-80:20-30;

[0013] When the filler is a mixture of microcrystalline cellulose and lactose, the weight ratio of microcrystalline cellulose to lactose is 60-80:20-30.

[0014] Preferably, the orodisintegrating cariprazine hydrochloride tablet comprises the following components in parts by weight: 1.5-2 parts of cariprazine hydrochloride, 90-94 parts of filler, 1-3 parts of disintegrant, 0.8-1.5 parts of glidant, 0.8-1.5 parts of sweetener and 0.3-1 parts of lubricant.

[0015] Further preferably, the orally disintegrating cariprazine hydrochloride tablet comprises the following components in parts by weight: 1.63 parts of cariprazine hydrochloride, 93.87 parts of filler, 2 parts of disintegrant, 1 part of glidant, 1 part of sweetener and 0.5 part of lubricant.

[0016] Preferably, the filler is a mixture of microcrystalline cellulose and mannitol, and the weight ratio of microcrystalline cellulose to mannitol is 63.87-73.87:20-30.

[0017] Further preferably, the weight ratio of microcrystalline cellulose to mannitol is 73.87:20.

[0018] Further preferably, the microcrystalline cellulose is spray-dried microcrystalline cellulose.

[0019] Preferably, the disintegrant is selected from at least one of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and polacrilin potassium.

[0020] Preferably, the glidant is colloidal silicon dioxide.

[0021] Preferably, the sweetener is selected from at least one of sucralose, aspartame, sucrose, steviol glycosides, acesulfame potassium, neotame and xylitol.

[0022] Preferably, the lubricant is magnesium stearate.

[0023] On the other hand, the present invention provides a method for preparing the above-mentioned cariprazine hydrochloride orally disintegrating tablets, comprising the steps of:

[0024] (1) Sieving: Pass cariprazine hydrochloride, filler, disintegrant, glidant, sweetener, and lubricant through a 50-80 mesh sieve to obtain the sieved components;

[0025] (2) Pretreatment: Mix the filler, disintegrant, glidant and sweetener prepared in step (1) to obtain a mixture A; mix cariprazine hydrochloride and 40-60% by weight of the mixture A to obtain a mixture B;

[0026] (3) Premixing: Mixing mixture B with the remaining weight of mixture A to obtain a premix;

[0027] (4) Total mixing: mixing the premix and the lubricant to obtain a mixture C;

[0028] (5) Tableting: Mixture C is tableted to obtain cariprazine hydrochloride orally disintegrating tablets.

[0029] Preferably, in step (1), the mesh size of the sieve is 60 meshes.

[0030] Preferably, step (2) specifically comprises: mixing the filler, disintegrant, glidant and sweetener of step (1) to obtain a mixture; taking cariprazine hydrochloride and 50% by weight of mixture A and mixing them evenly to obtain mixture B;

[0031] Preferably, in step (5), the tabletting parameters are: single punch pressure 10-20 kN, main tabletting thickness 0.5-1.8 mm, filling depth 1.5-9.7 mm.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] 1. The orodisintegrating cariprazine hydrochloride tablets prepared by the present invention include cariprazine hydrochloride, fillers, disintegrants, glidants, sweeteners and lubricants; wherein the filler is a mixture of microcrystalline cellulose and mannitol, or a mixture of microcrystalline cellulose and lactose; orodisintegrating cariprazine hydrochloride tablets of different specifications prepared by using fillers of specific ingredients have similar dissolution behaviors in media of pH=1.2, pH=4.5 and pH=6.8; the present invention provides technical support for bioequivalence studies between products of different specifications.

[0034] 2. The present invention adopts a powder mixing direct compression process to prepare orally disintegrating cariprazine hydrochloride tablets of different specifications. The preparation method does not require a granulation and drying process. The fluidity and compressibility of the orally disintegrating cariprazine hydrochloride tablets meet production requirements and have high stability. DETAILED DESCRIPTION

[0035] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0036] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs.

[0037] The present invention is further described below by way of specific examples. Unless otherwise specified, the various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels.

[0038] In the following examples, the microcrystalline cellulose was purchased from Jiangsu Xidian Pharmaceutical Excipients Co., Ltd., model PH-102SCG; the mannitol was purchased from Roquette (Roquette Company), model 160C; the cross-linked sodium carboxymethyl cellulose was purchased from JRS (Ruidenmeier Company), model VIVASOL; the colloidal silicon dioxide was purchased from Hubei Huifu Nanomaterial Co., Ltd., model HL-200. The products of different manufacturers of the above components have no significant effect on the effect.

[0039] In the present invention, " / " means that the component is not used or the data does not exist.

[0040] Example 1-Example 5

[0041] The cariprazine hydrochloride orally disintegrating tablets of Examples 1 to 5 have a formula as shown in Table 1:

[0042] Table 1

[0043]

[0044] In Table 1, the specifications of cariprazine hydrochloride orodisintegrating tablets are based on cariprazine; that is, the 1.5 mg orodisintegrating tablets refer to: containing 1.5 mg cariprazine (1.63 mg cariprazine hydrochloride).

[0045] The cariprazine hydrochloride orally disintegrating tablets of Examples 1 to 5 are prepared by:

[0046] (1) Sieving: Passing cariprazine hydrochloride, filler, cross-linked sodium carboxymethyl cellulose, colloidal silicon dioxide, xylitol, sucralose, and magnesium stearate through a 60-mesh sieve to obtain the sieved components;

[0047] (2) Pretreatment: the filler of step (1), cross-linked sodium carboxymethyl cellulose, colloidal silicon dioxide, xylitol, and sucralose are mixed to obtain a mixture A; cariprazine hydrochloride is mixed with half the weight of the mixture A to obtain a mixture B;

[0048] (3) Premixing: Mixing mixture B with the remaining weight of mixture A to obtain a premix;

[0049] (4) Total mixing: mixing the premix and magnesium stearate to obtain a mixture C;

[0050] (5) Tableting: Mixture C is tableted. The tableting parameters of cariprazine hydrochloride orally disintegrating tablets of different specifications are as follows:

[0051] 1.5mg specification: single punch pressure 13.6kN, main tablet thickness 0.5mm, filling depth 1.5mm;

[0052] 3.0mg specification: single punch pressure 16.8kN, main tablet thickness 0.6mm, filling depth 6.4mm;

[0053] 4.5mg specification: single punch pressure 16.8kN, main tablet thickness 1.8mm, filling depth 9.7mm;

[0054] 6.0mg specification: single punch pressure 17.1kN, main tablet thickness 1.7mm, filling depth 9.2mm.

[0055] The powder properties of the mixture C obtained in step (4) of Examples 1 to 5 were tested. The test results are shown in Table 2:

[0056] Table 2

[0057]

[0058] The dissolution behavior of the cariprazine hydrochloride orally disintegrating tablets prepared in Examples 1 to 5 was tested in different pH media.

[0059] The dissolution behavior results of the cariprazine hydrochloride orally disintegrating tablets prepared in Examples 1 to 5 in a medium with a pH of 1.2 are shown in Table 3. The cariprazine hydrochloride orally disintegrating tablets of various specifications all achieved rapid dissolution within 15 min, and the dissolution behaviors were similar.

[0060] Table 3

[0061]

[0062] The dissolution behavior results of the cariprazine hydrochloride orally disintegrating tablets prepared in Examples 1 to 5 in a medium with a pH of 4.5 are shown in Table 4. The cariprazine hydrochloride orally disintegrating tablets of various specifications all achieved rapid dissolution within 15 min, and the dissolution behaviors were similar.

[0063] Table 4

[0064]

[0065] The dissolution behavior of the orally disintegrating cariprazine hydrochloride tablets prepared in Example 1 in a medium with a pH of 6.8 is shown in Table 5. The similarity factors (f2, dissolution behavior compared with the 1.5 mg specification) of the orally disintegrating cariprazine hydrochloride tablets of various specifications in a medium with a pH of 6.8 are all greater than 50, and the dissolution behaviors are similar.

[0066] Table 5

[0067]

[0068] The dissolution behavior of the orally disintegrating cariprazine hydrochloride tablets prepared in Example 2 in a medium with a pH of 6.8 is shown in Table 6. The similarity factors (f2, dissolution behavior compared with the 1.5 mg specification) of the orally disintegrating cariprazine hydrochloride tablets of each specification in a medium with a pH of 6.8 are all greater than 50, and the dissolution behaviors are similar.

[0069] Table 6

[0070]

[0071] The dissolution behavior of the orally disintegrating cariprazine hydrochloride tablets prepared in Example 3 in a medium with a pH value of 6.8 is shown in Table 7. The similarity factors (f2, dissolution behavior compared with the 1.5 mg specification) of the orally disintegrating cariprazine hydrochloride tablets of various specifications in a medium with a pH value of 6.8 are all greater than 50, and the dissolution behaviors are similar.

[0072] Table 7

[0073]

[0074] The dissolution behavior of the orally disintegrating cariprazine hydrochloride tablets prepared in Example 4 in a medium with a pH value of 6.8 is shown in Table 8. The similarity factors (f2, dissolution behavior compared with the 1.5 mg specification) of the orally disintegrating cariprazine hydrochloride tablets of various specifications in a medium with a pH value of 6.8 are all greater than 50, and the dissolution behaviors are similar.

[0075] Table 8

[0076]

[0077] The dissolution behavior of the orally disintegrating cariprazine hydrochloride tablets prepared in Example 5 in a medium with a pH value of 6.8 is shown in Table 9. The similarity factors (f2, dissolution behavior compared with the 1.5 mg specification) of the orally disintegrating cariprazine hydrochloride tablets of various specifications in a medium with a pH value of 6.8 are all greater than 50, and the dissolution behaviors are similar.

[0078] Table 9

[0079]

[0080] Example 6-Example 7

[0081] The formula of the cariprazine hydrochloride orally disintegrating tablets of Example 6-Example 7 is shown in Table 10:

[0082] Table 10

[0083]

[0084] The preparation method of the orally disintegrating cariprazine hydrochloride tablets of Examples 6 and 7 is the same as that of Example 1.

[0085] The dissolution behavior results of Example 6-Example 7 are:

[0086] In pH=1.2, pH=4.5, and pH=5.0 media, rapid dissolution was achieved within 15 min;

[0087] In the medium of pH=6.8, the dissolution behavior of Example 6 is similar to that of Example 2, and the dissolution behavior of Example 7 is similar to that of Example 1. The similarity factor (f2, dissolution behavior compared with the 1.5 mg specification) of each specification of cariprazine hydrochloride orodisintegrating tablets in the medium of pH=6.8 is greater than 50, and the dissolution behavior is similar.

[0088] The dissolution results of Example 6 in a medium with a pH value of 6.8 are shown in Table 11, and the dissolution results of Example 7 in a medium with a pH value of 6.8 are shown in Table 12.

[0089] Table 11

[0090]

[0091] Table 12

[0092]

[0093] Comparative Example 1-Comparative Example 3

[0094] The cariprazine hydrochloride orally disintegrating tablets of Comparative Examples 1 to 3 were prepared according to Chinese invention patent CN107970217A, respectively. The specific prescriptions are shown in Table 13.

[0095] Table 13

[0096]

[0097] The dissolution behavior results of the cariprazine hydrochloride orally disintegrating tablets prepared in Comparative Example 1 in a medium with a pH value of 6.8 are shown in Table 14. The similarity factors (f2, dissolution behavior compared with the 1.5 mg specification) of the cariprazine hydrochloride orally disintegrating tablets of each specification in the medium with a pH value of 6.8 were all less than 50, and the dissolution behaviors were quite different.

[0098] Table 14

[0099]

[0100] The dissolution behavior results of the cariprazine hydrochloride orally disintegrating tablets prepared in Comparative Example 2 in a medium with pH=6.8 are shown in Table 15.

[0101] Table 15

[0102]

[0103] The dissolution behavior results of the cariprazine hydrochloride orally disintegrating tablets prepared in Comparative Example 3 in a medium with pH=6.8 are shown in Table 16.

[0104] Table 16

[0105]

[0106] Comparative Example 4

[0107] The difference from Example 1 is that the cariprazine hydrochloride orally disintegrating tablet does not contain microcrystalline cellulose, and the microcrystalline cellulose is replaced by lactose. The rest is the same as Example 1.

[0108] Comparative Example 5

[0109] Different from Example 1, the filler in the cariprazine hydrochloride orodisintegrating tablets is only microcrystalline cellulose, and the filler accounts for 93.87% of the cariprazine hydrochloride orodisintegrating tablets. The rest is the same as Example 1.

[0110] The dissolution behavior results of the cariprazine hydrochloride orally disintegrating tablets prepared in Comparative Example 4 in a medium with pH=6.8 are shown in Table 17.

[0111] Table 17

[0112]

[0113] The dissolution behavior results of the cariprazine hydrochloride orally disintegrating tablets prepared in Comparative Example 5 in a medium with pH=6.8 are shown in Table 18.

[0114] Table 18

[0115]

[0116] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A cariprazine hydrochloride orally disintegrating tablet with different specifications and similar dissolution behavior, characterized in that: The invention is composed of the following components by weight: 1.5-2 parts of cariprazine hydrochloride, 90-94 parts of filler, 1-3 parts of disintegrant, 0.8-1.5 parts of colloidal silicon dioxide, 0.8-1.5 parts of sweetener and 0.3-1 parts of magnesium stearate; The filler is a mixture of microcrystalline cellulose and mannitol, or a mixture of microcrystalline cellulose and lactose; When the filler is a mixture of microcrystalline cellulose and mannitol, the weight ratio of microcrystalline cellulose to mannitol is 60-80:20-30; When the filler is a mixture of microcrystalline cellulose and lactose, the weight ratio of microcrystalline cellulose to lactose is 60-80:20-30; The disintegrant is cross-linked carboxymethyl cellulose sodium.

2. The orally disintegrating tablet of cariprazine hydrochloride according to claim 1, characterized in that The invention is composed of the following components by weight: 1.63 parts of cariprazine hydrochloride, 93.87 parts of filler, 2 parts of disintegrant, 1 part of colloidal silicon dioxide, 1 part of sweetener and 0.5 part of magnesium stearate.

3. The orally disintegrating tablet of cariprazine hydrochloride according to any one of claims 1 to 2, characterized in that: The filler is a mixture of microcrystalline cellulose and mannitol, and the weight ratio of microcrystalline cellulose to mannitol is 63.87-73.87:20-30.

4. The orally disintegrating tablet of cariprazine hydrochloride according to claim 3, characterized in that: The weight ratio of microcrystalline cellulose to mannitol is 73.87:

20.

5. The orally disintegrating tablet of cariprazine hydrochloride according to any one of claims 1 to 2, characterized in that: The sweetener is selected from at least one of sucralose, aspartame, sucrose, steviol glycosides, acesulfame potassium, neotame and xylitol.

6. The method for preparing the orally disintegrating cariprazine hydrochloride tablets according to any one of claims 1 to 5, characterized in that: Includes steps: (1) Sieving: Passing cariprazine hydrochloride, filler, disintegrant, colloidal silicon dioxide, sweetener, and magnesium stearate through a 50-80 mesh sieve to obtain the sieved components; (2) Pretreatment: the filler, disintegrant, colloidal silicon dioxide and sweetener of step (1) are mixed to obtain a mixture A; cariprazine hydrochloride is mixed with 40-60% by weight of the mixture A to obtain a mixture B; (3) Premixing: Mixing mixture B with the remaining weight of mixture A to obtain a premix; (4) Total mixing: mixing the premix and magnesium stearate to obtain a mixture C; (5) Tableting: Mixture C is tableted to obtain cariprazine hydrochloride orally disintegrating tablets.

7. The preparation method according to claim 6, characterized in that: In step (1), the mesh size of the sieve is 60 mesh; Step (2) specifically comprises: mixing the filler, disintegrant, colloidal silicon dioxide and sweetener of step (1) to obtain a mixture A; taking cariprazine hydrochloride and 50% by weight of the mixture A and mixing them evenly to obtain a mixture B; In step (5), the tabletting parameters are: single punch pressure 10-20 kN, main tabletting thickness 0.5-1.8 mm, filling depth 1.5-9.7 mm.